Endpoints News, with data provided by DealForma, reports that biopharma dealmaking accelerated in Q2 2026, driven by record M&A and licensing activity, a reopening IPO market, and continued investment in later-stage assets, signaling a broad industry recovery. Read it here
DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.
Database
Company
Comparisons
Website Design by Once Interactive
